|1.||Dean, Brian: 6 articles (12/2015 - 05/2007)|
|2.||Scarr, Elizabeth: 6 articles (12/2015 - 05/2007)|
|3.||Dean, B: 5 articles (11/2009 - 03/2000)|
|4.||McBrien, Neville A: 4 articles (08/2012 - 01/2002)|
|5.||Huang, Xu-Feng: 4 articles (05/2012 - 03/2004)|
|6.||Walline, Jeffrey J: 3 articles (01/2016 - 01/2003)|
|7.||Zavitsanou, Katerina: 3 articles (01/2007 - 03/2004)|
|8.||Crook, J M: 3 articles (06/2001 - 03/2000)|
|9.||Copolov, D L: 3 articles (06/2001 - 03/2000)|
|10.||Deng, Chao: 2 articles (05/2012 - 09/2005)|
|1.||Duodenal Ulcer (Curling's Ulcer)
11/25/1987 - "Pirenzepine 100 mg administered at night is therefore an effective treatment for gastric and duodenal ulcers."
01/01/1985 - "Although the tricyclic selective anticholinergic pirenzepine has been effective in treating duodenal ulcer, it is not approved in the United States and its role in the treatment of duodenal ulcer is not yet well defined. "
01/01/1982 - "Pirenzepine appears to be an effective drug for the short-term treatment of duodenal ulcer. "
01/01/1982 - "Pirenzepine (100 mg/day for six weeks) should be an effective and safe treatment for duodenal ulcers."
01/01/1982 - "The published world literature on the efficacy of pirenzepine, a new anti-muscarinic agent, in the treatment of gastric and duodenal ulcer is reviewed. "
04/01/1993 - "Pirenzepine can be regarded as an effective agent for the control of postoperative gastric hypersecretion and possibly a good prophylactic for postoperative stress ulcers."
01/01/1991 - "Pirenzepine 1, 2.5 and 5 mg/kg every 2 h all caused a significant reduction in mean total ulcer length (p less than 0.01) compared to controls. "
08/01/1987 - "Thus pirenzepine is effective in ulcer prevention even if administered in an interrupted manner."
05/12/1986 - "In an endoscopic controlled trial the effectiveness of pirenzepine in preventing stress ulcer in high risk patients for surgical operation was studied. "
06/01/1980 - "[Stress-ulcer prevention with pirenzepine-a controlled study]."
04/05/2005 - "The significant reduction in myopia in 2% and 4% pirenzepine treated animals was caused by significantly less vitreous chamber elongation and axial elongation of the deprived eyes [2% group: (0.009+/-0.052) mm, 4% group: (0.006+/-0.078) mm] when compared with untreated, saline treated or 1% pirenzepine treated guinea pigs (0.057+/-0.056) mm, (0.064+/-0.053) mm and (0.033+/-0.035) mm, respectively]. "
09/01/1995 - "Daily subconjunctival injection of pirenzepine was significantly less effective in preventing form deprivation myopia. "
08/01/2008 - "To evaluate if the safety and efficacy of the relatively selective M1-antagonist, pirenzepine, in slowing the progression of myopia in children is sustained over a 2-year period. "
10/13/2004 - "Pirenzepine, an M1 selective muscarinic antagonist, is effective in slowing the progression of myopia in both humans and experimental animals, including chick. "
01/01/2002 - "Similar patterns of scleral glycosaminoglycan synthesis changes were found following the provision of brief periods of unoccluded vision further demonstrating that pirenzepine is effective in myopia prevention via a non-toxic mechanism. "
|4.||Peptic Ulcer (Peptic Ulcers)
11/10/1986 - "Pirenzepine is an antimuscarinic drug highly selective for M1 receptors, which proved to be effective in the treatment of peptic ulcer. "
01/01/1980 - "These results suggest that pirenzepine might be especially useful in the treatment of those patients with peptic ulcer who have high proteolytic activity of their gastric juice."
11/01/1985 - "Although pirenzepine appears effective in peptic ulcer, the results obtained in different centers have not been uniform. "
01/01/1986 - "A modified x-ray method was applied in 41 patients with peptic ulcer of the duodenum to study twice (without gastrozepin intake and after its administration in courses) the rate of evacuation from the gastrointestinal tract (GIT) of radiographic contrast capsules taken with a trial meal. "
11/08/1982 - "[Multicenter controlled clinical studies on the effectiveness of pirenzepin in the treatment of peptic ulcer]."
|5.||Stomach Ulcer (Gastric Ulcer)
11/01/1988 - "In a double-blind randomised four-center trial 43 patients with gastric ulcer (20 men, 23 women; mean age 52.2 years) were treated with either pirenzepine (P) 50 mg b.i.d. "
09/30/1982 - "In two studies the beneficial effect of Pirenzepine in the treatment of peptic duodenal and gastric ulcers was investigated in 1686 outpatients. "
01/01/1982 - "In 4 randomized double-blind placebo-controlled studies in which 84 patients with gastric ulcer were admitted, the healing rates were similar (50% when daily dosage of pirenzepine was 75 mg or less, 72% when the dosage ranged from 100 to 150 mg). "
01/01/1982 - "Therapeutic effect of pirenzepine dihydrochloride on gastric ulcer evaluated by a double-blind controlled clinical study. "
11/01/1988 - "In gastric ulcer, treatment with pirenzepine 50 mg b.i.d. "
|7.||Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
|8.||bismuth tripotassium dicitrate (bismuth subcitrate)
|9.||Gallamine Triethiodide (Gallamine)
|1.||Intensive Care (Surgical Intensive Care)
|3.||Drug Therapy (Chemotherapy)